The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
10 2023
Historique:
revised: 19 04 2023
received: 08 03 2023
accepted: 23 05 2023
medline: 29 9 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: ppublish

Résumé

Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease. Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score >56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.

Identifiants

pubmed: 37494275
doi: 10.1002/art.42619
pmc: PMC10543651
mid: NIHMS1930282
doi:

Substances chimiques

Calcium Pyrophosphate X69NU20D19

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1703-1713

Subventions

Organisme : NIAMS NIH HHS
ID : K23 AR075070
Pays : United States
Organisme : NIAMS NIH HHS
ID : L30 AR070514
Pays : United States

Informations de copyright

© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Osteoarthritis Cartilage. 2019 May;27(5):781-787
pubmed: 30738145
Ann Rheum Dis. 2018 Aug;77(8):1194-1199
pubmed: 29535120
Osteoarthritis Cartilage. 2021 May;29(5):619-632
pubmed: 33577959
Arthritis Care Res (Hoboken). 2022 Oct;74(10):1649-1658
pubmed: 33973414
Ann Rheum Dis. 2003 Jun;62(6):513-8
pubmed: 12759286
Clin Rheumatol. 2017 Mar;36(3):641-647
pubmed: 27837341
Ann Rheum Dis. 1957 Dec;16(4):494-502
pubmed: 13498604
Semin Arthritis Rheum. 2018 Aug;48(1):9-11
pubmed: 29338885
Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-834
pubmed: 35439343
Clin Exp Rheumatol. 2009 Nov-Dec;27(6):981-4
pubmed: 20149316
Ann Rheum Dis. 2011 Apr;70(4):563-70
pubmed: 21216817
J Clin Epidemiol. 2014 Jun;67(6):706-14
pubmed: 24721558
Arthritis Rheumatol. 2021 Apr;73(4):687-692
pubmed: 33131218
RMD Open. 2022 Jun;8(2):
pubmed: 35701012
Clin Exp Rheumatol. 2016 Mar-Apr;34(2):254-60
pubmed: 26886247
Rheumatology (Oxford). 2023 Apr 3;62(4):1493-1500
pubmed: 35997554
Ann Rheum Dis. 2019 May;78(5):634-640
pubmed: 30692164
Ann Rheum Dis. 1999 May;58(5):261-3
pubmed: 10225806
J Rheumatol. 2017 Nov;44(11):1744-1749
pubmed: 28250136
Arthritis Rheumatol. 2015 Oct;67(10):2557-68
pubmed: 26352873
Arthritis Care Res (Hoboken). 2023 Mar;75(3):682-688
pubmed: 36426584
Clin Rheumatol. 2018 Oct;37(10):2847-2853
pubmed: 29882204
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):819-28
pubmed: 16396700
J Rheumatol. 1989 Sep;16(9):1241-5
pubmed: 2810282
Ann Rheum Dis. 2019 Sep;78(9):1151-1159
pubmed: 31383717
J Clin Rheumatol. 2016 Oct;22(7):369-71
pubmed: 27660935
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):99-106
pubmed: 31140401
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arthritis Rheumatol. 2023 Apr;75(4):630-638
pubmed: 36122187
Rheumatology (Oxford). 2020 Apr 1;59(4):900-903
pubmed: 31630175

Auteurs

Abhishek Abhishek (A)

Academic Rheumatology, University of Nottingham, Nottingham, UK.

Sara K Tedeschi (SK)

Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

Tristan Pascart (T)

Department of Rheumatology, Lille Catholic University, Saint-Philibert Hospital, Lille, France.

Augustin Latourte (A)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Nicola Dalbeth (N)

Department of Medicine, University of Auckland, Auckland, New Zealand.

Tuhina Neogi (T)

Department of Medicine, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts.

Amy Fuller (A)

Academic Rheumatology, University of Nottingham, Nottingham, UK.

Ann Rosenthal (A)

Department of Medicine, Medical College of Wisconsin, Milwaukee.

Fabio Becce (F)

Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Thomas Bardin (T)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Hang Korng Ea (HK)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Georgios Filippou (G)

Rheumatology Department, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

John FitzGerald (J)

David Geffen School of Medicine, University of California, and Veterans Administration for Greater Los Angeles, Los Angeles, California.

AnnaMaria Iagnocco (A)

Academic Rheumatology Center, Università degli Studi di Torino, Turin, Italy.

Frédéric Lioté (F)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, Service de Rhumatologie, AP-HP, Lariboisière Hospital, and Université Paris Cité, Faculté de Santé, Paris, France.

Geraldine M McCarthy (GM)

School of Medicine and Medical Science, University College Dublin, and Mater Misericordiae University Hospital, Dublin, Ireland.

Roberta Ramonda (R)

Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.

Pascal Richette (P)

Université de Paris, INSERM, UMR-S 1132 BIOSCAR, and Service de Rhumatologie, AP-HP, Lariboisière Hospital, Paris, France.

Francisca Sivera (F)

Department of Rheumatology, Hospital General Universitario Elda, Elda, Spain, and Department of Clinical Medicine, Universidad Miguel Hernandez, Elche, Spain.

Mariano Andres (M)

Department of Medicine, Rheumatology Section, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Alicante, Spain.

Edoardo Cipolletta (E)

Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.

Michael Doherty (M)

Academic Rheumatology, University of Nottingham, Nottingham, UK.

Eliseo Pascual (E)

Rheumatology Division, Cruces University Hospital, Bilbao, Spain.

Fernando Perez-Ruiz (F)

Arthritis Investigation Group, Biocruces-Bizkaia Health Research Institute, Spain, Department of Medicine, Medicine and Nursing School, University of the Basque Country, and Basque Country Rheumatology Society, Bilbao, Spain.

Alexander So (A)

Lausanne University Hospital, Lausanne, Switzerland.

Tim L Jansen (TL)

VieCuri Medical Centre, Venlo, The Netherlands, and Medical Cell BioPhysics Group, University of Twente, Enschede, The Netherlands.

Minna J Kohler (MJ)

Department of Medicine, Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.

Lisa K Stamp (LK)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Janeth Yinh (J)

Department of Medicine, Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.

Antonella Adinolfi (A)

Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Uri Arad (U)

Department of Rheumatology, Te Whatu Ora-Health New Zealand Waikato, Hamilton, New Zealand.

Thanda Aung (T)

Division of Rheumatology, University of California, Los Angeles.

Eva Benillouche (E)

Department of Rheumatology, Lausanne University Hospital, Lausanne, Switzerland.

Alessandra Bortoluzzi (A)

Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, and Azienda Ospedaliera-Universitaria di Ferrara, Cona (FE), Italy.

Jonathan Dau (J)

Department of Medicine, Rheumatology Unit, Massachusetts General Hospital, Boston.

Ernest Maningding (E)

Highland Hospital, Oakland, California.

Meika A Fang (MA)

David Geffen School of Medicine, University of California, and Veterans Administration for Greater Los Angeles, Los Angeles, California.

Fabiana A Figus (FA)

Rheumatology Division, Local Health Unit (ASL), Turin-3, Collegno and Pinerolo, Italy.

Emilio Filippucci (E)

Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.

Janine Haslett (J)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Matthijs Janssen (M)

VieCuri Medical Centre, Venlo, The Netherlands.

Marian Kaldas (M)

David Geffen School of Medicine, University of California, Los Angeles.

Maryann Kimoto (M)

David Geffen School of Medicine, University of California, Los Angeles.

Kelly Leamy (K)

Mater Misericordiae University Hospital, Dublin, Ireland.

Geraldine M Navarro (GM)

Division of Rheumatology, University of California, Los Angeles, California.

Piercarlo Sarzi-Puttini (P)

Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy.

Carlo Scirè (C)

Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

Ettore Silvagni (E)

Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, and Azienda Ospedaliera-Universitaria di Ferrara, Cona (FE), Italy.

Silvia Sirotti (S)

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

John R Stack (JR)

School of Medicine and Medical Science, University College Dublin, and Mater Misericordiae University Hospital, Dublin, Ireland.

Linh Truong (L)

Division of Rheumatology, University of California, Los Angeles, California.

Chen Xie (C)

Division of Rheumatology, University of California, Los Angeles, California.

Chio Yokose (C)

Harvard Medical School, Boston, Massachusetts.

Alison M Hendry (AM)

Department of Medicine, General Medicine and Rheumatology, Middlemore Hospital, Counties Manukau Health District, New Zealand.

Robert Terkeltaub (R)

San Diego Veterans Administration Healthcare Service, and University of California, San Diego.

William J Taylor (WJ)

Department of Medicine, Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.

Hyon K Choi (HK)

Department of Medicine, Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH